Monica Lane
Associate Director, Genomic Medicine & Bioanalytics Characterization Sanofi
With over 20 years of in-depth experience in proteomics, analytical chemistry and mass spectrometry, I have successfully advanced analytical platforms at various stages of drug development, from target discovery to preclinical to clinical and commercialization. As the Senior Director of Mass Spectrometry and Proteomics at Gritstone bio, I led a proteogenomic and AI/ML driven mass spectrometry-based platform and coached a team enabling the discovery and development of novel immunotherapies for cancer and infectious diseases. I have extensive analytical development experience supporting CMC regulatory filings in both early-stage development (screening drug candidates and derisking molecular liabilities) and late-stage development (process qualification, methods validation and transfer). My background spans protein chemistry, proteomics, clinical biomarkers, and large molecule drug development which includes managing multi-disciplinary teams handling a broad range of biomolecule analytics.
Seminars
Proteomics analysis is driven by sensitive and fast instrumentation, but sample preparation remains a critical bottleneck, especially when working with limited or low-quality data. To fully realize the potential of scalable proteomics for drug discovery, it's crucial that sample preparation workflows are accelerated and optimized.
This workshop will gather experts to discuss how to:
- Transition to scalable, automated sample processing with plate-based formats, minimizing hands-on steps, accounting for variation in sample collection, and adopting automation tools
- Overcome poor sample quality with optimized protocols for low-abundance samples, effective enrichment strategies, and methods to reduce protein loss during preparation
- Uphold quality control standards during assay development, sample collection, processing, and storage to maintain sample integrity and facilitate reproducible proteomics analysis
